Atualização 1 de 1Mais recenteDia 2
FDA orders GLP-1 eye-risk warnings: what the numbers mean
The class-wide warning concerns rare, potentially permanent vision loss. The evidence warrants attention—not blanket advice to abandon treatment.
VerFonte mais antigaU.S. Food and Drug Administration
O que sabíamos inicialmente
- 6.4Probable events per 100,000 person-years: GLP-1 treatment
- 3.8Probable events per 100,000 person-years: comparison treatment
- 15Probable events across both trial groups